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Background: Ginsenoside Rp1 (G-Rp1) is a novel ginsenoside derived from ginsenoside Rk1. This com-
pound was reported to have anticancer, anti-platelet, and anti-inﬂammatory activities. In this study, we
examined the molecular target of the antiproliferative and proapoptotic activities of G-Rp1.
Methods: To examine the effects of G-Rp1, cell proliferation assays, propidium iodine staining, proteomic
analysis by two-dimensional gel electrophoresis, immunoblotting analysis, and a knockdown strategy
were used.
Results: G-Rp1 dose-dependently suppressed the proliferation of colorectal cancer LoVo cells and
increased their apoptosis. G-Rp1 markedly upregulated the protein level of apolipoprotein (Apo)-A1 in
LoVo, SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3 cells. The knockdown of Apo-A1 by its small-
interfering RNA increased the levels of cleaved poly(ADP-ribose) polymerase and p53 and diminished the
proliferation of LoVo cells.
Conclusion: These results suggest that G-Rp1 may act as an anticancer agent by strongly inhibiting cell
proliferation and enhancing apoptosis through upregulation of Apo-A1.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Unlike other ginsenosides with various pharmacological activ-
ities (e.g., ginsenoside Rg3) [1,2], ginsenoside Rp1 (G-Rp1) is a
ginseng saponin artiﬁcially prepared from crude ginsenosides (e.g.,
G-Rg5 and G-Rk1) obtained from Panax ginsengMeyer by reduction
andhydrogenation [3]. Thephytochemical featuresofG-Rp1 include
its chemical stability, and various pharmacological approaches have
suggested its value as a biologically active ginsenoside. It has been
reported that G-Rp1 is able to prevent skin papillomagenesis
induced by 7,12-dimehtylbenz(a) anthracene [4], suppress the pro-
liferation and metastatic processes of cancer cells [5], and reverse
multidrug resistance in tumor cells [6]. In addition, G-Rp1 has also
been found to block interleukin-1 production and diminish platelet
activation and thrombus formation [7,8]. It has also been revealed
that G-Rp1 blocks pathways linked to multidrug resistance gene-1
(MRD-1), Src, Akt, and I-kappaB kinase (IKK) in apoptotic andgineering, Sungkyunkwan Universi
pital, National Cancer Center, 323
echo@skku.edu (J.Y. Cho).
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e Korean Society of Ginseng, Publinﬂammatory processes [6,9,10]. Although these experiments have
explored the potential mechanisms underlying the anticancer and
anti-inﬂammatory activities of G-Rp1, the proteins responsible for
these pharmacological actions remain unclear. Therefore, in this
study, we used proteomic analysis to investigate the effect of G-Rp1
on theproteinproﬁles andexpression levels in several cancer cells to
understand the mechanisms underlying its anticancer activity.
2. Materials and methods
2.1. Materials
G-Rp1 (Fig. 1) of 97% purity dissolved in 100% dimethylsulfoxide
was prepared using established protocols [3]. 3-(4,5-Dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and propidium
iodide (PI) were purchased from SigmaeAldrich (St. Louis, MO,
USA). Polyvinylidenediﬂuoride membrane was purchased fromty, 2066 Seobu-ro, Suwon 440-746, Korea.
Ilsan-ro, Goyang 410-769, Korea.
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
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Fig. 1. The chemical structure of ginsenoside-Rp1.
J Ginseng Res 2014;38:251e255252Bio-Rad Laboratories, Inc. (Hercules, CA, USA). Phospho- or total
antibodies to apolipoprotein (Apo)-A1, cleaved poly(ADP-ribose)
polymerase (c-PARP), p85/phosphoinositide 3-kinase, AKT, extra-
cellular signal-regulated kinase (ERK), Src, p65/nuclear factor-kB,
p53 and b-actin were purchased from Cell Signaling (Beverly, MA,
USA). LoVo, SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3
cells were obtained from the Korean Cell Line Bank (Seoul, Korea).
2.2. Cell lines and culture
LoVo, SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3 cells
were maintained in RPMI 1640 medium supplemented with 10%
fetal bovine serum (Gibco, Grand Island, NY, USA) and an antibiotic
cocktail (100 U/mL penicillin and 100 mg/mL streptomycin), and
were subcultured by trypsinization every 3e4 days. Cells were
grown at 37C and 5% CO2 in humidiﬁed air.
2.3. Two-dimensional gel electrophoresis-based comparative
proteomics
Two-dimensional gel electrophoresis (2-DE) analysis was per-
formed as described previously [10]. A 0.15-mg protein sample was
applied to 13-cm immobilized nonlinear gradient strips (pH 3e10),
focused at 8,000 V within 3 hours, and separated on 10% poly-
acrylamide gels (Serva, Heidelberg, Germany; Bio-Rad). The 2-DE
gels were stained with Colloidal Coomassie Blue (Invitrogen,
Carlsbad, CA, USA) for 24 hours and then destained with deionized
water. Proteins showing abnormal expression were subjected to
matrix-associated laser desorption/ionizationemass spectroscopy
(MALDI-MS) analysis for identiﬁcation.
2.4. Cell viability assay
After preincubation of LoVo cells (1106 cells/mL) for 18 hours,
G-Rp1 (0e60mM) was added to the cell suspensions and incubated
for 24 hours. The cytotoxic effect of G-Rp1was then evaluated using
a conventional MTT assay, as previously reported [11,12]. Three
hours prior to culture termination, 10 mL MTT solution (10 mg/mL
in phosphate-buffered saline, pH 7.4) was added, and the cells were
continuously cultured until termination of the experiment. Incu-
bation was halted by addition of 15% sodium dodecyl sulfate (SDS)
into each well, solubilizing the formazan [13]. The absorbance at
570 nm (OD570e630) was measured using a Spectramax 250
microplate reader (BioTex, Bad Friedrichshall, Germany).
2.5. Flow-cytometric analysis of DNA fragmentation
Flow-cytometric analysis for PI staining was performed as
described previously [14,15]. LoVo (106) cells were washed with
PBS, ﬁxed in ethanol, suspended in PI solution (1 mg/mL RNase A,50 micro g/mL PI, and 0.1% Triton X-100 in 3.8mM sodium citrate)
and incubated on ice for 30 minutes in the dark. After washing
three times with ﬂuorescence activated cell sorting (FACS) buffer, PI
ﬂuorescent intensity was analyzed on a FACScan (Becton Dickinson,
Franklin Lakes, NJ, USA).
2.6. 2-DE
LoVo cells incubated with G-Rp1 were harvested and suspended
in 0.5 mL sample buffer consisting of 40mM Tris, 5M urea (Merck,
Darmstadt, Germany), 2M thiourea (SigmaeAldrich), 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate
(SigmaeAldrich), 10mM dithiothreitol (Merck), 1mM EDTA
(Merck), and a mixture of protease inhibitors (Roche Diagnostics,
Basel, Switzerland) for 45 minutes at room temperature. After
centrifugation at 16,000 g for 15 minutes, 150 mg protein was dis-
solved in rehydration buffer and applied to both the basic and acidic
ends of the 13-cm immobilized pH 3e10 nonlinear gradient strips
(Life Technologies, Carlsbad, CA, USA). Proteins were focused at
8,000 V within 3 hours. Immobilized pH gradient strips were
rehydrated using 250 mL of each paired preparation. Once isoelec-
tric focusing was completed, the strips were equilibrated in equil-
ibration buffer for 10 minutes. The second dimension was
performed using 10% SDS-polyacrylamide gel electrophoresis
(PAGE) at 20mA per gel. The gels were stained using a colloidal blue
staining kit (Life Technologies) for 24 hours, and destained with
deionized water. Melanie 7.0 software (Swiss Institute of Bioinfor-
matics, Geneva, Switzerland) was used for protein pattern evalua-
tion analysis of the 2-DE gels, as reported previously [16]. Proteins
with abnormal levels were subjected to MALDI-MS analysis for
identiﬁcation.
2.7. Mass analysis and data alignment
2-DE gels containing the proteins of interest were excised,
destained, and dried in a SpeedVac evaporator (Thermoscientiﬁc,
Waltham, MA, USA). Dried gel pieces were rehydrated with 30 mL
25mM sodium bicarbonate containing 50 ng trypsin (Promega,
Madison, WI, USA) at 37C overnight. a-Cyano-4-hydroxycinnamic
acid (10 mg; AB Sciex, Foster City, CA, USA) was dissolved in 1 mL
50% acetonitrile in 0.1% triﬂuoroacetic acid, and 1 mL of the matrix
solution was mixed with an equivalent volume of sample. Analysis
was performed using a 4700 Proteomics Analyzer TOF/TOF system
(AB Sciex). The TOF/TOF systemwas set to positive ion reﬂect mode.
Mass spectrawere ﬁrst calibrated in the closed external mode using
the 4700 proteomics analyzer calibration mixture (AB Sciex) and
analyzed with GPS Explorer software, version 3.5 (AB Sciex). The
acquired MS/MS spectra were searched against SwissProt and NCBI
databases using an in-house version of MASCOT.
2.8. Preparation of cell lysates and nuclear fractions for
immunoblotting and immunoprecipitation
Cancer cells (5  106 cells/mL) were washed three times in cold
PBS containing 1mM sodium orthovanadate and lysed in lysis
buffer (20mM TriseHCl, pH 7.4, 2mM EDTA, 2mM ethyl-
eneglycotetraacetic acid, 50mM b-glycerophosphate, 1mM sodium
orthovanadate, 1mM dithiothreitol, 1% Triton X-100, 10% glycerol,
10 mg/mL aprotinin, 10 mg/mL pepstatin, 1mM benzimide, and 2mM
phenylmethylsulfonyl ﬂuoride) for 30 minutes with rotation at 4C.
The lysates were clariﬁed by centrifugation at 16,000  g for 10
minutes at 4C and stored at20C until needed.Whole cell lysates
were then analyzed using immunoblotting analysis [17]. Proteins
were separated on 10% SDS-polyacrylamide gels and transferred by
electroblotting to a polyvinylidenediﬂuoride membrane.
Fig. 2. The effect of G-Rp1 on cell proliferation and DNA fragmentation. (A) LoVo cell proliferation was determined by a conventional MTT assay. (B) Flow-cytometric cell cycle
analysis of untreated and G-Rp1-treated cells was performed by propidium iodide staining. LoVo (106) cells were exposed to 1.5mM hydroxyurea for 14 hours and then treated with
G-Rp1 for 12 hours and 24 hours. Cell samples were analyzed for DNA content by ﬂow cytometry. Data are presented as the mean  standard error of the mean of three independent
observations performed in triplicate. *p < 0.05 compared to normal group. G-Rp1 ¼ ginsenoside-Rp1; MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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taining 3% fetal bovine serum, 20mM NaF, 2mM EDTA, and 0.2%
Tween 20 at room temperature. The membranes were incubated
for 1 hour with speciﬁc primary antibodies at 4C, washed three
times with the same buffer, and incubated for an additional 1 hour
with horseradish-peroxidase-conjugated secondary antibodies.
The total and phosphorylated levels of Apo-A1, c-PARP, p85/phos-
phoinositde 3-kinase, AKT, extracellular signal-regulated kinase,Fig. 3. Identiﬁcation of G-Rp1-inducible proteins in LoVo cells. (A) 2-DE gel images showing
2-DE gel images demonstrate that the proteins indicated by the white arrows were signiﬁcan
analysis. The protein indicated in Fig. 2A was unambiguously identiﬁed as Apo-A1. Mass ana
MS ¼ Matrix-assisted laser desorption/ionization mass spectrometry; Apo-A1 ¼ apolipoproSrc, p65/nuclear factor-kB, p53, and b-actin were visualized using
an ECL system (Amersham, Little Chalfont, Bucks, UK), as reported
previously [18,19].
2.9. Statistical analysis
Data are expressed as the mean  standard error of the mean.
For statistical comparison, results were analyzed using analysis ofdifferential protein levels between normal LoVo or G-Rp1-treated LoVo cells. Enlarged
tly up-regulated in G-Rp1-treated LoVo cells. (B) Identiﬁcation of Apo-A1 by MALDI-MS
lysis data are shown in the table. 2-DE ¼ two-dimensional gel electrophoresis; MALDI-
tein-A1; G-Rp1 ¼ ginsenoside-Rp1.
Fig. 4. Determination of Apo-A1 level in G-Rp1-treated cancer cells. (A, B) Cells were incubated with G-Rp1 for 48 hours. Total levels of Apo-A1 and b-actin in total lysates were
determined by immunoblotting analysis. Apo-A1 ¼ apolipoprotein-A1; G-Rp1 ¼ ginsenoside-Rp1.
Fig. 5. Effect of siApo-A1 in G-Rp1-treated cancer cells. (A) The effect of siApo-A1
treatment was evaluated by analyzing major signaling molecules and transcription
factors in LoVo cells by immunoblotting analysis. (A) The proliferation of siApo-A1-
treated LoVo cells was determined by a conventional MTT assay. Data are presented as
the mean  standard error of the mean of three independent observations, performed
in triplicate. siApo-A1 ¼ small interfering apolipoprotein-A1; G-Rp1 ¼ ginsenoside-
Rp1; MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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statistically signiﬁcant. All statistical tests were carried out using
the computer program STATISTICA version 4.5 (StatSoft Inc., Tulsa,
OK, USA).
3. Results and discussion
To understand the mode of action of the antiproliferative and
proapoptotic activities of G-Rp1, we ﬁrst examined whether G-Rp1
was able to block the proliferation of LoVo colorectal cancer cells. As
shown in Fig. 2A, G-Rp1 dose-dependently suppressed up to 70% of
the proliferation of LoVo cells at 60mM. Although the anti-
proliferative activity of G-Rp1 in colorectal cancer cells is weaker
than in human breast cancer cells [9], the inhibition of LoVo cell
proliferation by G-Rp1 indicates that this compound may have
common antiproliferative activity regardless of the cell type.
Indeed, PI staining strongly implied that the G-Rp1-induced anti-
proliferative activity was due to the induction of proapoptotic ac-
tivity by this compound. Thus, G-Rp1 treatment dose- and time-
dependently enhanced DNA fragmentation as assessed by PI
staining (Fig. 2B), similar to that observed in previous studies [9,20].
Unlike previous approaches that have examined apoptosis-
inducing mechanisms of G-Rp1 [20], this study used proteomic
analysis to determine the mode of action of G-Rp1. As Fig. 3A de-
picts, many proteins bands could be detected in LoVo cells using 2-
DE. After preparing whole cell lysates with G-Rp1-treated LoVo
cells, the blotting patterns between these samples were compared.
As shown in Fig. 3A, most band patterns appeared similar, although
several bands (indicated with white arrows in Fig. 3A) were strik-
ingly increased in G-Rp1-treated cells. To determine which bands
showed higher expression patterns, we further analyzed the
biochemical properties of these bands using proteomic analysis. As
Fig. 3B indicates, the bands were revealed to be Apo-A1; a major
component of high-density lipoprotein that regulates reverse
cholesterol transport by modulating the levels of cholesterol and
phospholipids in cells [21], and helps control inﬂammatory re-
sponses and oxidative stress [22]. The induction level of Apo-A1 in
G-Rp1-treated LoVo cells was also conﬁrmed by immunoblotting
analysis of other cancer cells such as SNU-407, DLD-1, SNU-638,
AGS, KPL-4, and SK-BR-3. Thus, Fig. 4 clearly indicates that the
protein level of Apo-A1 was strikingly enhanced with G-Rp1
treatment, suggesting its involvement in the mechanism of action
of G-Rp1.
To evaluate further the regulatory mechanism of G-Rp1-medi-
ated apoptosis, small-interfering (si)RNA for Apo-A1 was intro-
duced into the G-Rp1-treated LoVo cells. As shown in Fig. 5A, c-
PARP and p53 were enhanced in siApo-A1-treated cells in the
presence of G-Rp1, implying that these proteins might participate
in G-Rp1-induced apoptotic activity. Indeed, siApo-A1 treatment
Fig. 6. Schematic diagram of ginsenoside-Rp1 action.
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there was no signiﬁcant difference (Fig. 5B). Importantly, the level
of c-PARP in normal cells under siApo-A1 exposure was clearly
upregulated, suggesting that Apo-A1 acts as an apoptosis-pre-
venting protein. Indeed, it was proposed that Apo-A1might act as a
regulator of tumor growth and metastasis [23]. However, consid-
ering that Apo-A1 is highly expressed in primary cancer cells rather
than just in the secondary state [24], it is possible that this protein
is involved in reversing malignant cells back into a normal cycle of
differentiation. Recent ﬁndings that Apo-A1 is capable of promot-
ing the cardiac differentiation of embryonic stem cells and inducing
pluripotent stem cells [25] support this assumption. Therefore, our
data and those of previous reports suggest that Apo-A1 is involved
in the antiproliferative and proapoptotic activities of G-Rp1, via
regulation of cancer cell differentiation. Relevant hypotheses
regarding the functional role of Apo-A1 in G-Rp1-mediated anti-
cancer activity will be further tested in upcoming projects.
In summary, we have demonstrated that G-Rp1 is capable of
suppressing the proliferation of colorectal cancer cells and
enhancing their apoptosis via enhanced levels of Apo-A1. The
protein levels of c-PARP and p53 were enhanced under siApo-A1
treatment, therefore, the Apo-A1-mediated anticancer effect of G-
Rp1 might be linked to the functional involvement of these pro-
teins, as summarized in Fig. 6. Future studies will examine the exact
molecular mechanism of Apo-A1-dependent G-Rp1 pharmacology
in terms of its differentiation-inducing activities.
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